Zobrazeno 1 - 10
of 176
pro vyhledávání: '"Darrell, White"'
Autor:
Arleigh McCurdy, Donna Reece, Martha L. Louzada, Darrell White, Stephen Parkin, Michael P. Chu, Rami Kotb, Hira Mian, Ibraheem Othman, Jiandong Su, Aniba Khan, Engin Gul, Suzanne Trudel
Publikováno v:
Blood Cancer Journal, Vol 14, Iss 1, Pp 1-9 (2024)
Abstract Given the early use of triplet and quadruplet regimens, most patients with multiple myeloma (MM) will be exposed and/or refractory to PIs, IMiDs, and anti-CD38 mAbs after first- or second-line treatment. Effective treatment for this group of
Externí odkaz:
https://doaj.org/article/c10a5855b43241bab5df62d88db58644
Autor:
Rayan Kaedbey, Donna Reece, Christopher P. Venner, Arleigh McCurdy, Jiandong Su, Michael Chu, Martha Louzada, Victor H Jimenez‐Zepeda, Hira Mian, Kevin Song, Michael Sebag, Julie Stakiw, Darrell White, Anthony Reiman, Muhammad Aslam, Rami Kotb, Debra Bergstrom, Engin Gul, Richard LeBlanc
Publikováno v:
eJHaem, Vol 5, Iss 3, Pp 474-484 (2024)
Abstract Multiple myeloma remains an incurable cancer mostly affecting older adults and is characterized by a series of remission inductions and relapses. This study aims to evaluate the outcomes in newly diagnosed transplant‐ineligible patients us
Externí odkaz:
https://doaj.org/article/49d1058872a84b93920792b53dddad46
Autor:
Mégane Tanguay, Jean Roy, Jiandong Su, Engin Gul, Donna Reece, Christopher P. Venner, Darrell White, Michael P. Chu, Victor H. Jimenez‐Zepada, Kevin Song, Arleigh Mccurdy, Hira Mian, Michael Sebag, Debra Bergstrom, Julie Stakiw, Anthony Reiman, Rami Kotb, Muhammad Aslam, Rayan Kaedbey, Martha Louzada, Richard LeBlanc
Publikováno v:
Cancer Medicine, Vol 13, Iss 21, Pp n/a-n/a (2024)
ABSTRACT Background Young patients ≤ 50 years old with multiple myeloma (MM) account for about 10% of cases and are underrepresented in the literature. Methods We explored disease characteristics, treatments, and outcomes following modern therapies
Externí odkaz:
https://doaj.org/article/f0b92324996b40328adc1134d709493e
Autor:
Darrell White, Gary J. Schiller, Sumit Madan, Suzanne Lentzsch, Evgeni Chubar, Noa Lavi, Dane R. Van Domelen, Ohad S. Bentur, Muhamed Baljevic
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
ObjectiveTo identify the optimal dose of selinexor in combination with pomalidomide and dexamethasone (SPd).MethodsAn analysis of efficacy and safety of 2 once-weekly selinexor regimens (60 mg and 40 mg) with pomalidomide and dexamethasone (SPd-60 an
Externí odkaz:
https://doaj.org/article/faf3645ed4d642638bc528022e510fa6
Autor:
Paul G. Richardson, Thierry Facon, Christopher P. Venner, Nizar J. Bahlis, Fritz Offner, Darrell White, Lionel Karlin, Lotfi Benboubker, Eric Voog, Sung‐Soo Yoon, Kenshi Suzuki, Hirohiko Shibayama, Xiaoquan Zhang, Miguel Villarreal, Philip Twumasi‐Ankrah, Richard Labotka, Robert M. Rifkin, Sagar Lonial, Shaji K. Kumar, S. Vincent Rajkumar, Philippe Moreau
Publikováno v:
eJHaem, Vol 4, Iss 4, Pp 995-1005 (2023)
Abstract Deeper responses are associated with longer survival in multiple myeloma (MM); however, limited data exist on the impact of response kinetics on outcomes. We investigated progression‐free survival (PFS) and duration of response (DOR) by re
Externí odkaz:
https://doaj.org/article/889b8a2ac5cb4c9cba095e412d3f7b15
Autor:
Julie Côté, Richard LeBlanc, Hira Mian, Michael P. Chu, Arleigh McCurdy, Esther Masih-Khan, Jiandong Su, Victor H. Jimenez-Zepeda, Kevin Song, Martha Louzada, Darrell White, Michael Sebag, Anthony Reiman, Julie Stakiw, Rami Kotb, Debra Bergstrom, Muhammad Aslam, Rayan Kaedbey, Christopher P. Venner, Engin Gul, Donna Reece
Publikováno v:
Blood Cancer Journal, Vol 13, Iss 1, Pp 1-10 (2023)
Abstract Autologous stem cell transplant (ASCT) remains an important option for eligible multiple myeloma (MM) patients as part of initial therapy. Using the Canadian Myeloma Research Group (CMRG) national database, we examined the details and outcom
Externí odkaz:
https://doaj.org/article/fb087ee0177d4902a6bafc2f90ec045f
Autor:
Arleigh McCurdy, Hira Mian, Richard LeBlanc, Victor H. Jimenez-Zepeda, Jiandong Su, Esther Masih-Khan, Alissa Visram, Martha Louzada, Kevin Song, Darrell White, Michael Sebag, Julie Stakiw, Anthony Reiman, Muhammad Aslam, Debra Bergstrom, Rami Kotb, Rayan Kaedbey, Engin Gul, Donna Reece, Christopher P. Venner
Publikováno v:
Blood Cancer Journal, Vol 13, Iss 1, Pp 1-6 (2023)
Abstract While most patients diagnosed with multiple myeloma (MM) receive initial therapy, reported attrition rates are high. Understanding attrition rates and characteristics of patients not receiving subsequent therapy is useful for MM stakeholders
Externí odkaz:
https://doaj.org/article/14c4decaca6e4a0bbfd717e2c08b1751
Autor:
Hira Mian, Richard LeBlanc, Martha Louzada, Esther Masih‐Khan, Arleigh McCurdy, Christopher P. Venner, Julie Stakiw, Moustafa Kardjadj, Victor H. Jimenez‐Zepeda, Michael Sebag, Darrell White, Muhammad Aslam, Kevin Song, Anthony Reiman, Rami Kotb, Engin Gul, Donna Reece
Publikováno v:
Cancer Medicine, Vol 12, Iss 4, Pp 4357-4362 (2023)
Abstract Using the Canadian Myeloma Research Group Database, a retrospective study of 167 newly diagnosed, transplant‐ineligible patients with multiple myeloma (MM) that received lenalidomide‐dexamethasone as front‐line treatment was conducted
Externí odkaz:
https://doaj.org/article/f086a93b14a2417f97d2b0f2547cfc26
Autor:
Stephanie A. Maier, Tobias Berg, Susan Berrigan, Jonathan Bramson, Chris Bredeson, Guy Cantin, Andrew Daly, Gwynivere A. Davies, Mahmoud Elsawy, Alejandro Garcia-Horton, Wilson Lam, Alix Lapworth, Kylie Lepic, Luciana Melo Garcia, Kirk R. Schultz, Ram Vasudevan Nampoothiri, Darrell White, Jean-Sébastien Delisle
Publikováno v:
Current Oncology, Vol 29, Iss 12, Pp 9970-10017 (2022)
On behalf of Cell Therapy Transplant Canada (CTTC), we are pleased to present the Abstracts of the CTTC 2022 Annual Conference. The conference was held in-person 15–18 June 2022, in Niagara Falls, Ontario. Poster authors presented their work during
Externí odkaz:
https://doaj.org/article/68ea8c1d5ffe42aa9ed762e1b2e8642a
Autor:
Arleigh McCurdy, Martha Louzada, Christopher P. Venner, Alissa Visram, Esther Masih‐Khan, Moustafa Kardjadj, Victor H. Jimenez‐Zepeda, Richard LeBlanc, Michael Sebag, Kevin Song, Darrell White, Hira Mian, Julie Stakiw, Anthony Reiman, Muhammad Aslam, Rami Kotb, Engin Gul, Donna Reece
Publikováno v:
eJHaem, Vol 3, Iss 4, Pp 1252-1261 (2022)
Abstract Carfilzomib is an active and commonly used treatment in patients with multiple myeloma (MM). Using the Canadian Myeloma Research Group Database, we performed a retrospective observational study of patients treated with carfilzomib for relaps
Externí odkaz:
https://doaj.org/article/1c70a968264b4965a924d97d53f6976e